Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at BTIG Research

Equities research analysts at BTIG Research initiated coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $50.00 price target on the stock. BTIG Research’s target price would indicate a potential upside of 57.58% from the stock’s previous close.

Separately, Piper Sandler initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday. They set an “overweight” rating and a $48.00 price target for the company. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $49.00.

Ascentage Pharma Group International Stock Performance

Shares of Ascentage Pharma Group International stock opened at $31.73 on Monday. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 52-week low of $16.50 and a 52-week high of $48.45. The company has a fifty day moving average of $37.24 and a 200-day moving average of $35.50.

Institutional Investors Weigh In On Ascentage Pharma Group International

Hedge funds have recently made changes to their positions in the company. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International in the third quarter worth about $204,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $96,000. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $610,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. Finally, Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International during the 2nd quarter valued at approximately $227,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.